HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- hydroxyarylidene- 4- cyclopentene- 1,3- dione

structure in first source

Also Known As:

TX-1123

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzylidene Compounds: 10
        2-hydroxyarylidene-4-cyclopentene-1,3-dione: 2
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclopentanes: 58
        2-hydroxyarylidene-4-cyclopentene-1,3-dione: 2

Experts

1.	Hori, Hitoshi: 2 articles (07/2016 - 03/2004)
2.	Ohkura, Kazuto: 2 articles (07/2016 - 03/2004)
3.	Uto, Yoshihiro: 2 articles (07/2016 - 03/2004)
4.	Kawaguchi, Yuki: 1 article (07/2016)
5.	Tatematsu, Yohei: 1 article (07/2016)
6.	Kirk, Kenneth L: 1 article (03/2004)
7.	Nagasawa, Hideko: 1 article (03/2004)
8.	Shimamura, Mariko: 1 article (03/2004)
9.	Uehara, Yoshimasa: 1 article (03/2004)

Related Diseases

1.	Neoplasms (Cancer) 03/11/2004 - "Secondly, as a further investigation of the promising power of this 4-cyclopentene-1,3-dione as an innovative pharmacophore, we discuss our strategy of development of hypoxia-targeting PTK inhibitor TX-1123 analogues, 2-nitroimidazole-aminomethylenecyclopentenediones, such as TX-2036, for cancer treatment, especially for pancreatic cancers, which have a high level of hypoxia." 07/01/2016 - "Tyrphostin AG17 was previously shown to be a potent tumor growth inhibitor, while AG17 induced apoptosis and inhibited activity of cyclin-dependent kinase 2. We herein describe the binding features of tyrphostin AG17 analogs, such as TX-1123, with Src kinase (Src-K). "
2.	Pancreatic Neoplasms (Pancreatic Cancer) 03/11/2004 - "Secondly, as a further investigation of the promising power of this 4-cyclopentene-1,3-dione as an innovative pharmacophore, we discuss our strategy of development of hypoxia-targeting PTK inhibitor TX-1123 analogues, 2-nitroimidazole-aminomethylenecyclopentenediones, such as TX-2036, for cancer treatment, especially for pancreatic cancers, which have a high level of hypoxia."
3.	Hypoxia (Hypoxemia) 03/11/2004 - "Secondly, as a further investigation of the promising power of this 4-cyclopentene-1,3-dione as an innovative pharmacophore, we discuss our strategy of development of hypoxia-targeting PTK inhibitor TX-1123 analogues, 2-nitroimidazole-aminomethylenecyclopentenediones, such as TX-2036, for cancer treatment, especially for pancreatic cancers, which have a high level of hypoxia."

Related Drugs and Biologics

1.	Cyclin-Dependent Kinase 2
2.	src-Family Kinases
3.	Growth Inhibitors
4.	4-cyclopentene-1,3-dione
5.	SF 6847